• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A process for the production of 3-vinylcephalosporin compounds of formula wherein R1 and R2 may be the same or different and are hydrogen or an organic radical using a Wittig reaction in which weak bases are used.
    公开号:US20010007029A1
    申请号:US09/792,800
    申请日:2001-02-23
    公开日:2001-07-05
    发明作者:Josef Wieser；Gerd Ascher；Johannes Ludescher；Herbert Sturm
    申请人:Josef Wieser；Gerd Ascher；Johannes Ludescher；Herbert Sturm；
    IPC主号:C07D501-00
    专利说明:
    [0001] The invention relates to an economical and simple process for the production of 3-vinylcephalosporin compounds of formula I [0001]
    [0002] wherein R[0002] 1 and R2 may be the same or different and denote hydrogen or an organic radical.
    [0003] The compounds of formula I are known to be useful starting products for the production of valuable 3-substituted vinyl cephalosporins. [0003]
    [0004] In substituents R[0004] 1 and R2, the organic radical may signify for example an optionally branched alkyl, alkenyl or alkinyl group; a totally or partially saturated cycloalkyl radical; or an optionally substituted aryl radical, aralkyl radical or heterocycle. The cycloalkyl radical, aryl radical, aralkyl radical or heterocycle may be substituted in any position, for example by halogen, nitrogen, sulphur, alkoxy, aryloxy, or a functional group such as a carbalkoxy or carboxamido group. R1 and R2 may also form part of an optionally substituted ring system.
    [0005] In a preferred embodiment of the invention one of R[0005] 1 and R2 is hydrogen and the other is:
    [0006] i) hydrogen, lower alkyl, lower alkenyl, or lower alkinyl; [0006]
    [0007] ii) lower cycloalkyl, lower cycloalkyl lower alkyl, aryl, (aryl)-lower alkyl, a heterocyclic group or a heterocyclyl-(lower)-alkyl, the ring of each of which may be optionally substituted by 1 to 3 lower alkoxy, lower alkylthio, halogen, lower alkyl, nitro, hydroxy, acyloxy, carboxy, carbalkoxy, lower alkylcarbonyl, lower alkylsulfonyl, lower alkoxysulfonyl, amino-(lower)-alkyl amino or acylamido groups; or [0007]
    [0008] iii) a group of formula —CH[0008] 2Z, in which Z is a) hydroxy, lower alkoxy, formyloxy, acetyloxy, lower alkylsulfonyloxy, halogen, N-mono(lower)alkylcarbamoyloxy, or N,N-di(lower)alkylcarbamoyloxy; b) a heterocyclic group; c) a group of formula —S(O)mR9 in which R9 is an aliphatic, araliphatic, alicyclic, aromatic or heterocyclic group, and m is 0, 1 or 2; or d) an acyclic or cyclic ammonium group.
    [0009] Suitable heterocyclic groups include single or fused heterocyclic rings having 4 to 7, preferably 5- or 6-atoms in each ring. Each ring has up to four hetero atoms in it selected from oxygen, nitrogen and sulphur. Also each heterocyclic ring may have 1 to 3 optional substituents selected from (C[0009] 1-4) alkyl, (C1-4) alkoxy, halogen, trihalo-(C1-4) alkyl, hydroxy, oxo, mercapto, amino, carboxyl, carbamoyl, di-(C1-4) alkylamino, carboxymethyl, carbamoylmethyl, sulfomethyl and methoxycarbonylamino.
    [0010] Examples of suitable heterocycle rings include unsubstituted and substituted imidazolyl, diazolyl, triazolyl, tetrazolyl, thiazolyl, thiadiazolyl, thiatriazolyl, oxazolyl, oxadiazolyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, triazolylpyridyl, purinyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazolyl and triazinyl. [0010]
    [0011] Preferably, suitable heterocycle rings include unsubstituted and substituted 5-hydroxy-4-pyridon-2-yl, 1,2,3-triazolyl; 1,2,4-triazolyl; tetrazolyl; oxazolyl; thiazolyl; 1,3,4-oxadiazolyl; 1,3,4-thiadiazolyl or 1,2,3-thiadiazolyl. Preferably the heterocycle is 1,5-dihydroxy-4-pyridon-2-yl, 5-hydroxy-1-methyl-4-pyridon-2-yl, 5-hydroxy-4-pyridon-2-yl, 1-methyl- 1H-tetrazol-5-yl-2-methyl- 1,3,4-thiadiazol-5-yl, 1-carboxymethyl-1H-tetrazol-5-yl, 6-hydroxy-2-methyl-5-oxo-2H-1,2,4-triazin-3-yl, 1,2,3 -triazol-5-yl, and 4-methyl-thiazol-5-yl. [0011]
    [0012] Examples of acyclic ammonium groups include (1-carbamoyl-2--hydroxyethyl)-dimethylammonium, (carbamoylmethyl)(ethyl)-methylammonium or trimethyl ammonium. [0012]
    [0013] Examples of cyclic ammonium groups are pyrrolidinium, which is N-substituted by alkyl, carbamoylalkyl, aminoalkyl or carboxyalkyl; pyridinium or cyclopentenopyridinium, which may be mono- or di-substituted by alkyl, halogen, hydroxy, carboxamido, alkoxycarbonyl, amino, monoalkylamino or dialkylamino. [0013]
    [0014] Except where otherwise indicated, the organic radicals preferably contain up to 10 carbon atoms and “lower” means the group has up to 4 carbon atoms. [0014]
    [0015] Processes for the production of compounds of formula I are known and are discussed in EP 0503453, the disclosure of which is incorporated by reference. However, as discussed in EP 0503453, these known processes require the use of expensive protection groups and require a multiplicity of intermediate stages. The invention disclosed in EP 0503453 addressed the problems of the prior art by making use of silyl protection groups in a Wittig reaction using 7-amino cephalosporanic acid as starting reagent. [0015]
    [0016] The process disclosed in EP 0503453 proceeds according to the following reaction scheme: [0016]
    [0017] i) a compound of the formula II [0017]
    [0018] in which R is a silyl protecting group, is reacted with a compound of the formula P(R[0018] 4)3 or P(OR4)3 to produce a compound of formula III
    [0019] in which X is —P(R[0019] 4)3.I or —P(O).(OR4)2, R is as defined above and R4 is a lower alkyl group or an aryl group;
    [0020] ii) the compound of the formula III is then reacted with a strong base to produce a compound of the formula IV [0020]
    [0021] in which X[0021] +is —P+(R4)3 or —P(O).(OR4)2.Y, R4 and R are as defined above and Y is a cation of the alkali series or the protonated form of a strong organic base; and
    [0022] iii) the compound of the formula IV is reacted with a compound of the formula V [0022]
    [0023] in which R[0023] 1 and R2 are as defined above, to produce the compound of the formula I. The resulting process is simple, economical and may be carried out in a single reaction vessel. Also, it has the advantage that the silyl protection groups are removable by simple hydrolysis or alcoholysis.
    [0024] The base used in step ii) is a strong organic base and guanidines (for example tetramethylguanidine), amidines (for example 1,8-diazabicyclo[5.4.0]undec-7-ene and 1,5-diazabicylo[4.3.0]non-5-ene), alkali salts of nitrogen-containing compounds (for example the Li or Na salts of 1,1,1,3,3,3-hexamethyldisilazane and Li-diisopropylamide), butyllithium, hydrides of alkali metals, and iminophosphoranes are given as suitable examples. It is also mentioned that the bases should be free of moisture and should not contain any parts that could be silylated, so as to maintain the degree of silylation of the product. [0024]
    [0025] It has now been surprisingly found that the process described in EP 0503453 may be carried out using weaker bases. This is of particular advantage since the reaction may be carried out under milder conditions. [0025]
    [0026] Therefore this invention provides a process, substantially as defined above, for the production of a compound of formula I which is improved by the use of a weak base in step ii). [0026]
    [0027] That a weaker base could be used in a Wittig reaction is indeed surprising. The use of the weaker base has the advantage that the possibility of opening the β-lactam ring is reduced and superfluous condensation of the base with the aldehyde or ketone is avoided or restricted. [0027]
    [0028] Preferably the weak base is such that its conjugate acid has a silylatable function and the reaction step ii) is carried out in the presence of a silylating agent to cause silylation of the silylatable function. Surprisingly, the reaction proceeds without the silyl protecting group on the 7-amino group, which is a very potent silylating agent and which is easily removed, being removed by the base or conjugate acid. If the silyl protecting group were to be removed during the reaction, the amino group would be free to react with the aldehyde or ketone of formula V and this would cause the reaction to collapse. Preferably the weak base is selected from: [0028]
    [0029] i) compounds that have the formula [0029]
    [0030] in which R[0030] 5 is hydrogen, alkyl or aryl; R6 and R7, which may be the same or different, are each an activated group of the formula —COOR8, —CN, —SO2R8, —COR8, or —CON(R8)2; or R5 and R6, which may be the same or different, are each aryl and R7 is an activated group of the formula —COOR8, —CN, —SO2R8, —COR8 or —CON(R8)2; W+is a cation (for example lithium, sodium, or calcium); and R8 is alkyl, cycloalkyl or aryl; and
    [0031] ii) salts of carboxylic acids of the formula R[0031] 10—COO−W+in which R10 is an optionally branched alkyl group or an optionally substituted aryl group; and W+is as defined above.
    [0032] Particularly preferred weak bases are lithium and sodium salts of malonic acid diethyl esters, acetoacetic acid esters, acetic acid, pivalic acid, or ethylhexanoic acids, or lithium salts of benzoic acids. [0032]
    [0033] The silylating agent may be added to the reaction mixture prior to the addition of the weak base or simultaneously with the weak base; in both cases to cause the silylation of silylatable function of the conjugate acid of the weak base. N,O-bis(trimethylsilyl)-acetamide and bissilylurea are particularly suitable as silylating agents and further examples are given in EP 0503453. [0033]
    [0034] The reaction may be carried in a suitable solvent or solvent mixture which is inert under the reaction conditions, for example an inert ether (such as tetra-hydrofuran, diethyl ether, an ethylene glycol dialkyl ether or a tert.butylmethyl ether), an inert amide (such as dimethylformamide, dimethylacetamide or N-methylpyrrolidone), an urea (such as tetra-methylurea, 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidone, or 1,3,2-imidazolidinone) a nitrile (such as acetonitrile), or a halogenated hydrocarbon (such as dichloromethane). [0034]
    [0035] Should a substituent of the aldehyde or the ketone of formula V contain a function which is easily silylated, this should be blocked temporarily with an appropriate silylation agent prior to the reaction. The amount of the compound of formula V may be stoichiometrical or in excess based on the amount of the compound of formula IV. [0035]
    [0036] The reaction may be carried out over a wide temperature range, preferably at a temperature of between −70° C. and +70° C. [0036]
    [0037] The compounds of formula I may be isolated in a conventional manner. The silyl protecting groups may be removed by simple hydrolysis or alcoholysis. This may be done either by adding the desilylation agent to the reaction mixture, or by extracting the product into a separable aqueous phase, adding water (under alkaline or acidic conditions) and precipitating by adjusting the pH value to the isoelectric point, optionally adding an organic solvent. [0037]
    [0038] The compounds of formula II are known and may be produced as described in EP 0503453. [0038]
    [0039] The compounds of formula I are important starting materials for the production of valuable cephalosporin antibiotics. Cephalosporins which are vinyl-substituted in 3-position are either resorbed orally, or when administered parenterally, are characterized for their very broad, efficient spectrum of activity. The following compounds may be produced for example: [0039]
    [0040] In the following examples, which illustrate the invention more fully, but in no way limit its scope, all temperatures are given in degrees celsius. [0040] EXAMPLE 1 7-Amino-3-(3-acetoxy-1-propenyl)-3-cephem-4-carboxylic acid
    [0041] 7.5 ml of N,O-bis(trimethylsilyl)acetamide is added to 25 ml of a dichloromethane solution containing 6 g of 7-trimethylsilylamino-3-triphenyl-phosphoniummethyl-3-cephem-4-carboxylic acid trimethylsilylester-iodide on ice. 25 ml of a N-Methylpyrrolidone solution, at 5 to 10°, containing 2.35 g sodium aceto-acetic acid ethyl ester, is added dropwise. The dark red solution is then cooled to 2° and 5.16 g acetoxyaldehyde is added dropwise. The reaction mixture is then stirred for 2 hours at 10° and then added to a mixture of 100 ml acetic acid and 100 ml water. The pH of the aqueous phase is adjusted to 7 with ammonia and the organic phase is separated off. The pH is adjusted to 3.5 by adding 1:1 diluted concentrated HCl, whereupon the title compound precipitates. The suspension is stirred for 30 minutes at 5°, the title compound is filtered off, washed in acetone and dried. [0041] EXAMPLE 2 7-Amino-3-(prop-1-enyl)-3-cephem-4-carboxylic acid
    [0042] 5 ml of N,O-bis(trimethylsilyl)acetamide is added to 25 ml of a dichloromethane solution containing 6 g of 7-trimethylsilylamino-3-triphenyl-phosphoniummethyl-3-cephem-4-carboxylic acid trimethylsilylester-iodide on ice. 25 ml of a N-Methylpyrrolidone solution, at 5 to 10°, containing 2.35 g sodium malonic acid diethyl ester, is added dropwise. Thereafter the solution is cooled to −10° and 1.32 g acetaldehyde, dissolved in 10 ml dichloromethane, is added. After the addition of the acetaldehyde, the reaction mixture is stirred for 48 hours at 0°. Thereafter the process proceeds as described in example 1. [0042] EXAMPLE 3 7-Amino-3-(prop-1-enyl)-3-cephem-4-carboxylic acid
    [0043] 36.5 ml of N,O-bis(trimethylsilyl)acetamide is added to 500 ml of a dichloromethane solution containing 24 g of 7-trimethylsilylamino-3-triphenyl-phosphoniummethyl-3-cephem-4-carboxylic acid trimethylsilylester-iodide at a temperature of −10°. A suspension of 12.8 g lithium benzoate in 75 ml N-Methylpyrrolidone is added. 9 g of acetaldehyde is added and the reaction mixture is stirred for 2 days at 0°. Superfluous acetaldehyde and most of the dichloromethane are removed in a rotary evaporator. The residue is then stirred in 1500 ml of water and then filtered. The residue is dissolved in 200 ml aqueous ammonia and the aqueous phase is extracted twice using 100 ml dichloromethane. After removal of the organic phase, 1:1 diluted concentrated HCl is added to the aqueous phase to bring the pH to 3.5 whereupon the title compound precipitates. The suspension is stirred for 30 minutes at 50°, the title compound is filtered off, washed in acetone and dried. [0043] EXAMPLE 4 7-Amino-3-(3-acetoxy-1-propen-1-yl)-3-cephem-4-carboxylic acid
    [0044] 7.5 ml of N,O-bis(trimethylsilyl)acetamide is added to 25 ml of a dichloromethane solution containing 6 g of 7-trimethylsilylamino-3-triphenyl-phosphoniummethyl-3-cephem-4-carboxylic acid trimethylsilylester-iodide on ice. 15 ml of a N-methylpyrrilidone solution containing 2.5 g sodium-ethylhexanoate is added dropwise at 0 to 5°. 5 ml of acetoxy-acetaldehyde is added dropwise. The reaction mixture is stirred overnight at 0° and then processed as described in example 1. [0044] EXAMPLE 5 7-Amino-3-[2-(4-methyl-5-thiazolyl)vinyl]-3-cephem-4-carboxylic acid
    [0045] 25 g of a dichloromethane solution containing 10.2 g of 7-trimethylsilylamino-3-triphenyl-phosphoniummethyl-3-cephem-4-carboxylic acid trimethylsilylester-iodide is cooled to a temperature of −10°. 4.7 ml of N,O-bis(trimethylsilyl)acetamide, 11 ml dimethylformamide and 1.1 g lithium acetate are added and the mixture stirred at 0 to 5° for 30 minutes. A solution of 2 g of 4-methyl-thiazol-5-carboxyaldehyde in 5 ml dichloromethane is then added dropwise. The mixture is then stirred for 10 hours at 30°, cooled to 10° and stirred for a further hour at 10°. The title compound is separated using a suction filter, washed with methanol and vacuum dried. [0045] EXAMPLE 6 7-Amino-3-(prop-1-enyl)-3-cephem-4-carboxylic acid
    [0046] 220.7 g of a dichloromethane solution containing 68.7 g of 7-trimethylsilylamino-3-triphenyl-phosphoniummethyl-3-cephem-4-carboxylic acid trimethylsilylester-iodide is cooled to a temperature of −10°. 58.4 ml of N,O-bis(trimethylsilyl)acetamide and 81 ml N,N-dimethylacetamide is added while stirring. A solution of 14.05 g lithium pivalate is added and the mixture stirred for 30 minutes at −10°. 17.2 ml of acetaldehyde is added and the reaction mixture is stirred for 90 minutes at −10° and then overnight at 0°. Superfluous acetaldehyde and some of the dichloromethane are removed in a rotary evaporator under vacuum and at 20°. The residue is then stirred into 500 ml of ice-cold water and 100 ml dichloromethane. The pH value is adjusted to 8.5 with aqueous ammonia. The phases are then separated and the aqueous phase is washed with 100 ml dichloromethane and combined with 200 ml acetone. The pH is adjusted to 3.5 with 1:1 diluted concentrated hydrochloric acid at 30° to precipitate the title compound. The suspension is held in the ice bath for 2 hours whilst stirring, and the title compound is isolated using a suction filter. The title compound is washed with a mixture of 100 ml of water and 50 ml acetone and then again with 50 ml of acetone. The title compound is then dried in a vacuum drying chamber at 40°. [0046]
    权利要求:
    Claims (7)
    [1" id="US-20010007029-A1-CLM-00001] 1. In a process for the production of a 3-vinylcephalosporin compound of formula I
    [2" id="US-20010007029-A1-CLM-00002] 2. A process according to
    claim 1 in which the conjugate acid of the weak base has an easily silylatable function and the reaction is carried out in the presence of a silylating agent.
    [3" id="US-20010007029-A1-CLM-00003] 3. A process according to
    claim 2 in which the weak base is selected from
    i) compounds that have the formula
    [4" id="US-20010007029-A1-CLM-00004] 4. A process according to
    claim 3 in which the weak base is a lithium or sodium salt of malonic acid diethyl ester, acetoacetic acid ester, acetic acid, pivalic acid, or ethylhexanoic acid, or is a lithium salt of benzoic acid.
    [5" id="US-20010007029-A1-CLM-00005] 5. A process according to
    claim 2 in which the silylating agent is added to the reaction mixture prior to the addition of the weak base.
    [6" id="US-20010007029-A1-CLM-00006] 6. A process according to
    claim 2 in which the silylating agent is added to the reaction mixture at the same time as the weak base.
    [7" id="US-20010007029-A1-CLM-00007] 7. A process according to
    claim 2 in which the silylating agent is N,O-bis(trimethylsilyl)acetamide or bissilylurea.
    类似技术:
    公开号 | 公开日 | 专利标题
    US6063917A|2000-05-16|Cephalosporin synthesis
    EP0503453B1|2001-05-09|New process for the production of cephalosporines and novel intermediates in this process
    MXPA96004353A|1997-06-01|Sistensis de cefalospori
    EP0233271A4|1988-10-20|Process for preparing cephalosporin intermediates.
    EP0112164A2|1984-06-27|Cephem compounds, and their production, and medicaments containing them
    EP0597429B1|2003-02-26|Process for the production of 3-vinylcephalosporins
    EP0175814B1|1990-05-23|Process for preparing cephem derivatives
    US6414140B2|2002-07-02|Process for the production of 3-vinyl cephalosporins
    KR100249581B1|2000-04-01|Process for producing 7-alpha-aminoacyl-cephalosporin
    US4145418A|1979-03-20|Thienopyridine substituted cephalosporins
    RO109652B1|1995-04-28|Hydrate dihydrochloride cefepim antibiotic preparation process
    FI88391C|1993-05-10|Process for the preparation of carboxylic acid amides
    US6169180B1|2001-01-02|Process for the production of cephalosporines
    KR0161796B1|1998-12-01|A process for preparing thiazolyl derivatives
    EP0305625B1|1992-12-02|Crystalline cephalosporine derivative
    US4231954A|1980-11-04|Dane salt and process for preparing aminopenicillins therefrom
    KR0182414B1|1999-05-01|The process for preparation of cephalosporin compounds
    IE51464B1|1986-12-24|New cephalosporin derivatives,their production and their use
    同族专利:
    公开号 | 公开日
    US6414140B2|2002-07-02|
    US6248881B1|2001-06-19|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US4110534A|1970-01-23|1978-08-29|Glaxo Laboratories Limited|Process for the preparation of 3-vinyl and substituted vinyl cephalosporins|
    US3769277A|1970-01-23|1973-10-30|Glaxo Lab Ltd|Preparation of delta3-4 carboxy cephalosporins having a 3-vinyl or substituted 3-vinyl group|
    GB1532682A|1976-04-27|1978-11-22|Bristol Myers Co|Process for the preparation of cephadroxil|
    US4406899A|1982-03-04|1983-09-27|Bristol-Myers Company|Cephalosporins|
    US4546101A|1982-09-10|1985-10-08|Fujisawa Pharmaceutical Co., Ltd.|New cephem compounds useful for treating infectious diseases in human being and animals and processes for preparation thereof|
    JPH059425B2|1983-03-10|1993-02-04|Ootsuka Kagaku Kk||
    GB2152497B|1983-11-28|1987-08-05|Otsuka Kagaku Kk|Process for the preparation of azetidinone derivatives|
    GB8411954D0|1984-05-10|1984-06-13|Glaxo Group Ltd|Cephalosporin antibiotics|
    US4705851A|1984-09-28|1987-11-10|Fujisawa Pharmaceutical Co., Ltd.|Process for the preparation of 3-phosphoniummethyl-3-cephem compounds|
    AT382873B|1984-11-23|1987-04-27|Biochemie Gmbh|Process for the preparation of cephalosporin derivatives|
    US4703118A|1985-04-08|1987-10-27|Eli Lilly And Company|Synthesis of 3-iodomethyl cephalosporins|
    US4699979A|1985-04-22|1987-10-13|Bristol-Meyers Company|7-amino-3-propenylcephalosporanic acid and esters thereof|
    US5171854A|1987-05-26|1992-12-15|Bayer Aktiengesellschaft|Substituted vinylcephalosporins|
    DE3734004A1|1987-05-26|1988-12-15|Bayer Ag|SUBSTITUTED VINYLCEPHALOSPORINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT|
    AU619201B2|1987-07-13|1992-01-23|Gist-Brocades N.V.|Process for the preparation of 3-exomethylene cepham derivatives|
    US5073551A|1988-03-30|1991-12-17|Sagami Chemical Research Center|Cephalosporin compounds|
    DE3933934A1|1989-10-03|1991-04-11|Bayer Ag|METHOD FOR PRODUCING 7-AMINO-3 - -1-PROPEN-1-YL) -3-CEPHEM-4-CARBONIC ACID|
    DE69231815T2|1991-03-08|2001-09-27|Biochemie Gmbh|Process for the preparation of cephalosporins and intermediates in this process|
    DE4107698A1|1991-03-09|1992-09-10|Dethleffs Gmbh|CAMPING VEHICLE|
    US5856474A|1994-04-25|1999-01-05|Biochemie Gesellschaft, M.B.H.|Cephalosporin synthesis|US20060173176A1|2002-10-08|2006-08-03|Yatendra Kumar|Process for the preparation of -isomer enriched 7-amino-3-propen-1-yl-3-cephem-4-carboxylic acid|
    JP5733856B2|2007-10-09|2015-06-10|ソファーミア，インコーポレイテッド|Broadband β-lactamase inhibitor|
    CA2905240A1|2013-03-12|2014-10-09|Gladius Pharmaceuticals Coproration|Derivatized 3-styryl-cephalosporins|
    法律状态:
    2003-04-29| CC| Certificate of correction|
    2005-12-30| FPAY| Fee payment|Year of fee payment: 4 |
    2009-12-02| FPAY| Fee payment|Year of fee payment: 8 |
    2014-02-07| REMI| Maintenance fee reminder mailed|
    2014-07-02| LAPS| Lapse for failure to pay maintenance fees|
    2014-07-28| STCH| Information on status: patent discontinuation|Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
    2014-08-19| FP| Expired due to failure to pay maintenance fee|Effective date: 20140702 |
    优先权:
    申请号 | 申请日 | 专利标题
    AT50491A|AT396106B|1991-03-08|1991-03-08|Novel process for the preparation of 3-vinylcephalosporin compounds|
    AT504/91||1991-03-08||
    ATA504/91||1991-03-08||
    AT101891A|AT396238B|1991-05-17|1991-05-17|Novel process and intermediates for the preparation of 3- vinylcephalosporin compounds|
    AT101/91||1991-05-17||
    US84845792A| true| 1992-03-09|1992-03-09||
    AT0221292A|AT400436B|1992-11-10|1992-11-10|NEW METHOD FOR PRODUCING 3-VINYLCEPHALOSPORINE COMPOUNDS|
    AT2212/92||1992-11-10||
    US08/069,239|US5401841A|1991-03-08|1993-05-28|Process for the production of cephalosporines|
    US14943193A| true| 1993-11-09|1993-11-09||
    US08/829,572|US6248881B1|1991-03-08|1997-03-31|Intermediates and process for the production of 3-vinyl cephalosporins|
    US09/792,800|US6414140B2|1991-03-08|2001-02-23|Process for the production of 3-vinyl cephalosporins|US09/792,800| US6414140B2|1991-03-08|2001-02-23|Process for the production of 3-vinyl cephalosporins|
    [返回顶部]